EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Anlotinib combined with temozolomide for brain metastases in small cell lung cancer with early recurrence after whole-brain radiotherapy: a case report

Bolun Jiang, Xiaojie Wang, Teng Zhang, Qilin Liu, Xia Zhang, Bin Zhang

Frontiers in Medicine · 08.05.2026 · 13

DOI: 10.3389/fmed.2026.1824583 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Medicine, online erschienen am 08.05.2026. Verfasst von Bolun Jiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: The First Hospital of Dalian Medical University, Dalian, Liaoning, China. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Small cell lung cancer (SCLC) is characterised by aggressive biological behaviour and a high propensity for early brain metastasis. Although whole-brain radiotherapy (WBRT) is a standard treatment modality, early intracranial relapse after WBRT remains prevalent and is associated with an exceedingly poor prognosis due to the paucity of effective salvage options. Case presentation We report the case of a 50-year-old male patient diagnosed with extensive-stage SCLC with brain and pancreatic metastases. The patient received first-line etoposide plus cisplatin(EP) chemotherapy and WBRT with simultaneous integrated boost, but experienced early intracranial and systemic progression approximately 7 months post-WBRT. Second-line immunotherapy-based treatment also failed to control disease progression. Consequently, the patient was administered oral anlotinib (12 mg, days 1–14) in combination with temozolomide (200 mg, days 1–5) as salvage therapy. The combination achieved durable intracranial disease control, significant systemic tumour regression, and deep tumour marker remission, with a progression-free survival of approximately 6 months.

Conclusion

The combination of anlotinib and temozolomide has been shown to demonstrate promising efficacy as a salvage treatment for patients with early recurrent brain metastases after WBRT in extensive-stage SCLC. This regimen represents a viable therapeutic option with a manageable safety profile and warrants further prospective evaluation in larger clinical trials.

Schlagwörter

Stichwörter der Autor:innen

anlotinibbrain metastasesmagnetic resonance imagingrecurrencesmall cell lung carcinomatemozolomide

Autor:innen und Institutionen

  • The First Hospital of Dalian Medical University, Dalian, Liaoning, China.
  • Department of Gastroenterology, University Town Hospital, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
  • The Second Hospital of Dalian Medical University, Dalian, Liaoning, China.
  • The Fifth People's Hospital of Dalian, Dalian, Liaoning, China.

Zitieren

APA

Jiang, B., Wang, X., Zhang, T., Liu, Q., Zhang, X., & Zhang, B. (2026). Anlotinib combined with temozolomide for brain metastases in small cell lung cancer with early recurrence after whole-brain radiotherapy: a case report. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1824583

Vancouver

Jiang B, Wang X, Zhang T, Liu Q, Zhang X, Zhang B. Anlotinib combined with temozolomide for brain metastases in small cell lung cancer with early recurrence after whole-brain radiotherapy: a case report. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1824583

BibTeX
@article{Jiang2026,
  author = {Jiang, Bolun and Wang, Xiaojie and Zhang, Teng and Liu, Qilin and Zhang, Xia and Zhang, Bin},
  title = {Anlotinib combined with temozolomide for brain metastases in small cell lung cancer with early recurrence after whole-brain radiotherapy: a case report},
  journal = {Frontiers in Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fmed.2026.1824583}
}
Kostenlos starten →